Spyre Therapeutics (SYRE) Capital Expenditures (2015 - 2023)
Spyre Therapeutics' (SYRE) quarterly Capital Expenditures came in at -$2.1 million in Q3 2023, down 206800.0% YoY from N/an in Q3 2022, and down 206800.0% on a QoQ basis from $1000.0 in Q3 2022.
Spyre Therapeutics (SYRE) Capital Expenditures (2015 - 2023) Analysis & Trends
Spyre Therapeutics (SYRE) has 9 years of Capital Expenditures data on file, last reported at -$2.1 million in Q3 2023.
- Quarterly Capital Expenditures fell 206800.0% year-over-year to -$2.1 million in Q3 2023, while the trailing twelve-month figure through Dec 2023 was -$2.1 million (down 5536.84% YoY) and the FY2022 annual result came in at $38000.0, down 93.37% from the prior year.
- Capital Expenditures fell to -$2.1 million in Q3 2023, from $1000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.7 million in Q2 2020 to a low of -$2.1 million in Q3 2023.
- A 5-year average of $227142.9 and a median of $105500.0 in 2019 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2020 — Capital Expenditures soared 2807.02% — and 2023, when it slumped 206800.0%.
- Tracing SYRE's Capital Expenditures over 5 years: stood at $38000.0 in 2019, then jumped by 2531.58% to $1.0 million in 2020, then slumped by 90.7% to $93000.0 in 2021, then tumbled by 98.92% to $1000.0 in 2022, then tumbled by 206800.0% to -$2.1 million in 2023.
- The last three Capital Expenditures figures came in at -$2.1 million (Q3 2023), $1000.0 (Q3 2022), and $37000.0 (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -2.07 Mn |
| Sep 30, 2023 | -2.07 Mn |
| Sep 30, 2022 | 1,000.00 |
| Sep 30, 2022 | 1,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Sep 30, 2021 | 93,000.00 |
| Sep 30, 2021 | 93,000.00 |
| Jun 30, 2021 | 30,000.00 |
| Jun 30, 2021 | 30,000.00 |
| Mar 31, 2021 | 450,000.00 |
| Mar 31, 2021 | 450,000.00 |
| Dec 31, 2020 | 1.00 Mn |
| Dec 31, 2020 | 1.00 Mn |
| Sep 30, 2020 | 566,000.00 |
| Sep 30, 2020 | 566,000.00 |
| Jun 30, 2020 | 1.66 Mn |
| Jun 30, 2020 | 1.66 Mn |
| Mar 31, 2020 | 1.06 Mn |
| Mar 31, 2020 | 1.06 Mn |